Today's Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals

    Today's Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug

  PR Newswire

  LONDON, February 20, 2013

LONDON, February 20, 2013 /PRNewswire/ --

Small-cap biotech stocks can provide big returns when they have a blockbuster
drug in their portfolio. As in the case of Incyte Corporation (NASDAQ: INCY),
the stock provided steep returns while the company's fortune is dependent on
just one drug. The company announced strong Q4 results and provided robust
outlook for the future performance. Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
also made impressive move on the strength of its obesity drug, Belviq. While
these companies carry higher risk profile, the returns also commensurate
risks. StockCall professionals have completed their technical analysis on
Incyte and Arena Pharmaceuticals; and these free reports are accessible by
registering at 

Incyte Bets on Baricitinib

Incyte's stock jumped after its results declaration. The company reported its
fourth quarter EPS at 14 cents per share, up from 44 cents in net loss it had
reported for the corresponding quarter of the last year. Its revenue also
showed the equally impressive improvement and jumped from $28.9 million to
$113.9 million. The stock is making good moves too as it logged 32 percent
return so far in this year. Incyte now expects its full year revenue to be in
the range of $210 million and $225 million. Sign up for the free technical
research on Incyte Corp. at 

Incyte is also big on collaborations and has inked deals with big names like
Novartis, with which it has exclusive rights arrangements for its super
performer drug Jakafi. The drug improved its revenue from $2 million to the
current level of $43.3 million. The company also collaborates with Eli Lilly
for Baricitinib. The drug is being developed as a potential treatment for RA.
Thus, Incyte has one well performing drug in its portfolio and another
potential blockbuster drug is in the pipeline. With good results and solid
outlook, the company is expected to perform well in to the future. These
catalysts also bode well for the stock price and Incyte comes across as a good
investment opportunity.

Arena Pharma Waits for EU Approval

Arena is in the news for its potential fat busting drug Belviq. The drug will
directly compete with Vivus developed Qsymia. While any anti-obesity drug
seems to have a readymade market with obesity rate higher than before, many
previous attempts have failed. Pfizer's Exubera failed to make its mark in the
market. Vivus' Qsymia also logged lower-than-expected sales numbers. This
makes the scenario rather bleak for Arena Pharma. Be sure to read our latest
technical research on Arena Pharmaceuticals Inc. by registering at 

The company also seeks EU approval for its drug. However, the path to approval
is not easy. The drug is already approved for sale in the U.S. Thus, the
company is not only grappling with uncertainty regarding the drug's
performance in the U.S. market, it is also skeptical about receiving EU
approval. Though, the chances of getting the drug rejected by the EU
authorities are minimal, but the process can take a long time.

On the plus side, Arena Pharma collaborates with Eisai for the drug's U.S.
launch. The collaboration will help the company in the more effective launch
and distribution of Belviq. The consensus expectations for the drug are on the
milder side. Hence, any good sales performance by the drug will prove to be a
major positive catalyst for the stock.

About is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

Contact: William T. Knight, Email:, Contact Number:
+1(646)396-9857 (9:00 am EST - 01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.